glimepiride has been researched along with Diabetic Glomerulosclerosis in 8 studies
glimepiride: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "glimepiride were evaluated in normoalbuminuric patients with type 2 diabetes mellitus." | 2.74 | Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. ( Bob, F; Bozdog, G; Dragos Jianu, C; Dumitrascu, V; Gadalean, F; Giju, S; Gluhovschi, C; Gluhovschi, G; Ianculescu, C; Marian, R; Petrica, L; Petrica, M; Ursoniu, S; Velciov, S; Vlad, A, 2009) |
| "Diabetic nephropathy was induced by a single dose of streptozotocin (STZ) (60 mg/kg, i." | 1.43 | Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats. ( Chandewar, AV; Mazumder, PM; Tripathi, AS, 2016) |
| " The present study concludes that bioavailability of SIL increases when co-administered chronically with GLIM in the management of DN animals, and the mechanism is supported by molecular modeling studies." | 1.42 | Does glimepiride alter the pharmacokinetics of sildenafil citrate in diabetic nephropathy animals: investigating mechanism of interaction by molecular modeling studies. ( Chandewar, A; Mazumder, PM; Timiri, AK; Tripathi, AS, 2015) |
| "001) increase in the bioavailability of GLIM in the presence of SIL in DN after the 1(st) dose of administration of the drug as compared to GLIM treated rat, whereas at the end of 6(th) week of drug administration, there were significant (p<0." | 1.40 | Evaluation of drug interaction of glimepiride with phosphodiesterase inhibitors type V in diabetic nephropathy. ( Chandewar, AV; Mazumder, PM; Tripathi, AS, 2014) |
| "Glimepiride was well-tolerated and there were no drug-related adverse events." | 1.29 | Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. ( Lange, C; Malerczyk, V; Metelko, Z; Mrzljak, V; Profozic, V; Rosenkranz, B, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Latif, RG | 1 |
| Ahmed, AF | 1 |
| Heeba, GH | 1 |
| Tripathi, AS | 3 |
| Mazumder, PM | 3 |
| Chandewar, AV | 2 |
| Umayahara, R | 1 |
| Yonemoto, T | 1 |
| Kyou, C | 1 |
| Morishita, K | 1 |
| Ogawa, T | 1 |
| Taguchi, Y | 1 |
| Inoue, T | 1 |
| Laakso, M | 1 |
| Rosenstock, J | 1 |
| Groop, PH | 1 |
| Barnett, AH | 1 |
| Gallwitz, B | 1 |
| Hehnke, U | 1 |
| Tamminen, I | 1 |
| Patel, S | 1 |
| von Eynatten, M | 1 |
| Woerle, HJ | 1 |
| Timiri, AK | 1 |
| Chandewar, A | 1 |
| Petrica, L | 1 |
| Petrica, M | 1 |
| Vlad, A | 1 |
| Dragos Jianu, C | 1 |
| Gluhovschi, G | 1 |
| Ianculescu, C | 1 |
| Dumitrascu, V | 1 |
| Giju, S | 1 |
| Gluhovschi, C | 1 |
| Bob, F | 1 |
| Ursoniu, S | 1 |
| Gadalean, F | 1 |
| Velciov, S | 1 |
| Bozdog, G | 1 |
| Marian, R | 1 |
| Rosenkranz, B | 1 |
| Profozic, V | 1 |
| Metelko, Z | 1 |
| Mrzljak, V | 1 |
| Lange, C | 1 |
| Malerczyk, V | 1 |
3 trials available for glimepiride and Diabetic Glomerulosclerosis
5 other studies available for glimepiride and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
Topics: Animals; Antioxidants; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diet, Hi | 2020 |
Evaluation of drug interaction of glimepiride with phosphodiesterase inhibitors type V in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Interactions; Hypoglycemic Ag | 2014 |
Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Function Tests; Male; Phosp | 2016 |
Does glimepiride alter the pharmacokinetics of sildenafil citrate in diabetic nephropathy animals: investigating mechanism of interaction by molecular modeling studies.
Topics: Animals; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetic Nephropathies; Disease Models, Animal; Dru | 2015 |
Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
Topics: Administration, Oral; Adult; Aged; Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic N | 1996 |